Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial
SAN DIEGO, Jan. 17 /PRNewswire-FirstCall/ -- Vical Incorporated
(Nasdaq: VICL ) today announced the receipt of a $2.1 million cash payment
MG, Inc. for costs associated with the ongoing Allovectin-7(R)
Immunotherapeutic for Metastatic Melanoma (AIMM) Phase 3 trial.
BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
NOVATO, Calif., Aug. 13 /PRNewswire-FirstCall/ -- BioMarin
Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that AnGes
Inc. (AnGes), BioMarin's marketing and distribution partner in Japan, has
submitted a Biologics License Application (BLA) for Naglazyme(R)
(galsulfase) to the Ja...
Vical Licensee AnGes MG Announces Positive Results of Phase 3
Angiogenesis Trial in Japan
SAN DIEGO, June 18, 2007 /PRNewswire-FirstCall/ -- Vical
Incorporated today announced that the company's licensee, AnGes
Inc. reported positive results following interim analysis of data
from the first 41 subjects to complete a Phase 3 trial of an
angiogenesis product candidate using Vical's D...
Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey
...nd is currently enrolling patients in the United States,
Canada and Europe. anges
MG, Inc., is funding the clinical trial under a
collaborative agreement wit...f at all; whether Vical will receive
all of the clinical trial funding from anges
under the collaborative
agreement; whether Allovectin-7(R) or any other pro...
Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial
...llion of cash payments
and equity investments from anges
MG, Inc., under a previously announced
In exchange for funding the trial, anges
received exclusive marketing
rights in Japan and o...les levels are achieved. Vical is obligated to pay anges
based on defined sales levels in ...
Vical Promotes Melanoma Awareness Month With Allovectin-7(R) Video Report
...nd is currently enrolling patients in the United
States, Canada and Europe. anges
MG, Inc., is funding the clinical trial
under a collaborative agreement wit...tin-7(R); whether
Vical will receive all of the clinical trial funding from anges
collaborative agreement, which will depend on continued developme...
Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
... Development Programs
-- The company's licensee, anges
MG, Inc. (AnGes), reported positive results fo...n of an Independent Data Monitoring Committee, anges
ended the trial early and is preparing an applicat... metastatic melanoma. The trial is being funded by anges
under a collaborative agreement with Vical.
AnGes in Biological Technology
Vical and AnGes MG Sign Letter of Intent for Pandemic Influenza Program
SAN DIEGO, Oct. 7 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq:
VICL) and AnGes
MG, Inc., have signed a non-binding Letter of Intent
indicating their mutual interest to license the development and marketing
rights for Vical's pandemic influenza DNA vaccines in Japan to AnGes. AnGes
Vical Licensee AnGes MG Files NDA in Japan for Collategene Angiogenesis Product
SAN DIEGO, March 28 /PRNewswire-FirstCall/ -- Vical Incorporated
(Nasdaq: VICL ) today announced the company's licensee, AnGes
reported submission on March 27, 2008, of a New Drug Application (NDA) to
the Japanese Ministry of Health, Labor and Welfare for its angiogenesis
Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs
...e results of an interim analysis in this trial on
those subjects who were enrolled by the end of March.
H5N1 Pandemic Influenza Vaccines
Vical and anges
MG, Inc., signed a non-binding Letter of Intent in
October indicating their mutual interest in licensing the development and
marketing rights for Vica...
World Gene Therapy Market to Reach $484 Million by 2015, According to New Report by Global Industry Analysts, Inc.
...ses of biotech, pharmaceutical companies, research, and academic institutions. Leading biotech companies operating in gene therapy marketplace include anges
MG Inc, Cell Genesys, GenVec, Genzyme Corporation, Introgen Therapeutics Inc, Oxford BioMedica, Shenzhen SiBiono GeneTech Co., Ltd, Targeted Genetics ...
Mergent, Inc. Announces Quarterly Rebalancing of HealthShares(TM) Indexes
...RMA SA (Euronext, Brussels: OME) PHOTOCURE ASA (Oslo, Norway: PHO) QLT INC. (TSE: QLTI) SINCLAIR PHARMA PLC (London Main Market, U.K.: SPH)
MG INC (Tokyo SE: 4563) APP PHARMACEUTICALS INC (NASDAQ: APPX ) ARPIDA AG (SWX, Switzerland: ARPN) BTG (London Main Market, U.K.: BGC) CYTOS BIOT...
Naglazyme Approved by Japanese Ministry of Health
...l Inc. (Nasdaq and SWX: BMRN) announced today that anges
Inc. (AnGes), BioMarin's marketing and distrib...ridosis VI ( MPS
"We are proud to work with anges
in bringing the first drug treatment
option to MPS...reement with AnGes
in December 2006, through which anges
obtained exclusive rights to market
Naglazyme in t...
Japanese Continue Relentless Biotech Stake in Midwest
...ining their university roles.
This change alone has stimulated a proliferation of new biotech companies. One notable example is the biotech company anges
MG, which listed its stock in September 2002 and was started by Ryuichi Morishita, an assistant professor at Osaka University (one of the prestigious ...